Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
-
TOPICS 2 articles
August 28, 2006
-
COMMENTARY/Government Increases Efforts to Promote Clinical Research
August 28, 2006
-
Blockbuster Sales of International Majors in 2005: Rankings of Companies and Therapeutic Areas Keiji Nakamura, Ph.D. Pharma Forum Institute, Kamakura, Japan http://www.pharma-fi.com/index.html
August 21, 2006
-
COMMENTARY 3 articles
August 7, 2006
-
5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
-
COMMENTARY:New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
-
COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
-
COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
-
Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
-
Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
-
COMMENTARY 3 articles
June 19, 2006
-
Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
-
Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
-
Incident in PI Trial in UK 5 articles
May 8, 2006
-
COMMENTARY 3 articles
April 24, 2006
-
New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
-
Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
-
JMA Needs to Establish New Partnership with LDP
April 17, 2006
-
COMMENTARY 4 articles
April 3, 2006
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…